Real-time Estimate
Cboe BZX
10:19:09 2024-05-21 am EDT
|
5-day change
|
1st Jan Change
|
29.46
USD
|
-0.22%
|
|
+3.11%
|
-26.06%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
4,331
|
8,716
|
2,455
|
1,139
|
7,023
|
5,524
|
-
|
-
|
Enterprise Value (EV)
1 |
3,877
|
8,837
|
3,322
|
2,470
|
8,315
|
6,628
|
7,019
|
7,611
|
P/E ratio
|
-14.1
x
|
-18.7
x
|
-4.28
x
|
-2.34
x
|
-10.2
x
|
-11.3
x
|
-9.8
x
|
-15.6
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
107
x
|
1,057
x
|
35.2
x
|
14.7
x
|
755
x
|
14.4
x
|
21.5
x
|
8.87
x
|
EV / Revenue
|
95.6
x
|
1,071
x
|
47.7
x
|
31.8
x
|
894
x
|
17.2
x
|
27.3
x
|
12.2
x
|
EV / EBITDA
|
-14.6
x
|
-18.6
x
|
-5.76
x
|
-4.89
x
|
-14
x
|
-131
x
|
-15
x
|
-39.8
x
|
EV / FCF
|
-15.1
x
|
-21.7
x
|
-6.5
x
|
-5.82
x
|
-15.7
x
|
-18.1
x
|
-14.1
x
|
-19.4
x
|
FCF Yield
|
-6.61%
|
-4.61%
|
-15.4%
|
-17.2%
|
-6.36%
|
-5.53%
|
-7.1%
|
-5.15%
|
Price to Book
|
9.02
x
|
151
x
|
-2.83
x
|
-0.91
x
|
-
|
-3.55
x
|
-4.21
x
|
-
|
Nbr of stocks (in thousands)
|
123,575
|
122,568
|
147,192
|
149,483
|
173,967
|
187,129
|
-
|
-
|
Reference price
2 |
35.05
|
71.11
|
16.68
|
7.620
|
40.37
|
29.52
|
29.52
|
29.52
|
Announcement Date
|
3/2/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
40.56
|
8.249
|
69.72
|
77.65
|
9.303
|
384.7
|
257.2
|
623
|
EBITDA
1 |
-266.2
|
-474.5
|
-576.6
|
-505.4
|
-593
|
-50.58
|
-467.9
|
-191
|
EBIT
1 |
-266.2
|
-474.5
|
-576.6
|
-512.2
|
-607.4
|
-374.3
|
-586.1
|
-393.4
|
Operating Margin
|
-656.41%
|
-5,751.99%
|
-827.12%
|
-659.65%
|
-6,528.75%
|
-97.32%
|
-227.86%
|
-63.15%
|
Earnings before Tax (EBT)
1 |
-288.6
|
-505.5
|
-586.5
|
-484.7
|
-653.3
|
-491.5
|
-637.8
|
-470.7
|
Net income
1 |
-260.6
|
-448.7
|
-562.5
|
-481.2
|
-643.2
|
-451.1
|
-551.1
|
-324.2
|
Net margin
|
-642.47%
|
-5,439.74%
|
-806.9%
|
-619.7%
|
-6,913.92%
|
-117.28%
|
-214.28%
|
-52.05%
|
EPS
2 |
-2.480
|
-3.800
|
-3.900
|
-3.260
|
-3.950
|
-2.602
|
-3.011
|
-1.889
|
Free Cash Flow
1 |
-256.2
|
-407.2
|
-511.2
|
-424.3
|
-529
|
-366.2
|
-498.4
|
-392.1
|
FCF margin
|
-631.72%
|
-4,936.74%
|
-733.23%
|
-546.46%
|
-5,686.62%
|
-95.21%
|
-193.79%
|
-62.95%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/2/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
12.89
|
1.694
|
73.75
|
0.338
|
1.87
|
1.826
|
1.641
|
4.091
|
1.745
|
211.1
|
4.296
|
4.298
|
145.3
|
38.36
|
55.45
|
EBITDA
1 |
-165.6
|
-151
|
-71.78
|
-124.1
|
-129.2
|
-124.5
|
-140.9
|
-156.1
|
-175.1
|
27.84
|
-141.5
|
-150
|
258.3
|
-
|
-
|
EBIT
1 |
-165.6
|
-151
|
-80.18
|
-124.1
|
-129.2
|
-126.2
|
-146.1
|
-157.7
|
-177.4
|
0.343
|
-185.8
|
-184.9
|
-69.09
|
-156.2
|
-146.2
|
Operating Margin
|
-1,285.22%
|
-8,914.76%
|
-108.72%
|
-36,715.98%
|
-6,910.8%
|
-6,909.26%
|
-8,903.05%
|
-3,854.61%
|
-10,167.11%
|
0.16%
|
-4,324.36%
|
-4,302.06%
|
-47.55%
|
-407.12%
|
-263.67%
|
Earnings before Tax (EBT)
1 |
-152.3
|
-201.3
|
-2.559
|
-140.2
|
-140.6
|
-142.7
|
-160.7
|
-179.5
|
-170.3
|
-36.16
|
-208.2
|
-203.7
|
-211.3
|
-170.5
|
-155.6
|
Net income
1 |
-147.2
|
-196.4
|
-9.856
|
-137.3
|
-137.6
|
-140.2
|
-157.9
|
-177
|
-168.1
|
-35.22
|
-184.1
|
-186.7
|
-74.41
|
-150
|
-135
|
Net margin
|
-1,142.15%
|
-11,593.68%
|
-13.36%
|
-40,632.84%
|
-7,357.81%
|
-7,675.58%
|
-9,622.12%
|
-4,326.55%
|
-9,635.99%
|
-16.68%
|
-4,286.08%
|
-4,344.32%
|
-51.21%
|
-391%
|
-243.47%
|
EPS
2 |
-1.010
|
-1.350
|
-0.0700
|
-0.9300
|
-0.9200
|
-0.9200
|
-0.9800
|
-1.080
|
-0.9600
|
-0.2000
|
-1.033
|
-1.039
|
-0.3039
|
-0.8760
|
-0.7675
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
5/5/22
|
8/4/22
|
11/3/22
|
2/23/23
|
5/4/23
|
8/3/23
|
11/2/23
|
2/22/24
|
5/2/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
121
|
867
|
1,331
|
1,292
|
1,104
|
1,495
|
2,087
|
Net Cash position
1 |
454
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-0.2555
x
|
-1.504
x
|
-2.633
x
|
-2.179
x
|
-21.83
x
|
-3.195
x
|
-10.93
x
|
Free Cash Flow
1 |
-256
|
-407
|
-511
|
-424
|
-529
|
-366
|
-498
|
-392
|
ROE (net income / shareholders' equity)
|
-72.1%
|
-192%
|
138%
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-47.5%
|
-67.2%
|
-65.5%
|
-58.8%
|
-109%
|
-82.7%
|
-82.2%
|
-
|
Assets
1 |
548.3
|
667.6
|
858.2
|
817.9
|
592
|
545.7
|
670.8
|
-
|
Book Value Per Share
2 |
3.890
|
0.4700
|
-5.900
|
-8.330
|
-
|
-8.320
|
-7.010
|
-
|
Cash Flow per Share
2 |
-
|
-3.390
|
-3.450
|
-2.840
|
-3.240
|
-2.950
|
-1.970
|
-
|
Capex
1 |
2.64
|
7.52
|
13.2
|
4.82
|
1.31
|
4.43
|
4.91
|
6.74
|
Capex / Sales
|
6.5%
|
91.14%
|
19%
|
6.21%
|
14.04%
|
1.15%
|
1.91%
|
1.08%
|
Announcement Date
|
3/2/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Last Close Price
29.52
USD Average target price
50.23
USD Spread / Average Target +70.16% Consensus |
1st Jan change
|
Capi.
|
---|
| -26.88% | 5.52B | | -3.15% | 89.69B | | +3.95% | 41.34B | | -10.51% | 33.72B | | +60.39% | 26.11B | | -20.09% | 14.63B | | -8.92% | 12.84B | | -11.46% | 11.66B | | -43.05% | 11.52B | | +5.09% | 8.92B |
Biopharmaceuticals
|